SCHEMBL3800895

SCHEMBL3800895

CC(=O)NC(=O)CC(O)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
TET2 Q6N021 6/20 0.41
TET3 O43151 2/20 0.41
TET1 Q8NFU7 1/20 0.41
OR51E2 Q9H255 1/20 0.39
GLS O94925 1/20 0.37
KDM4A O75164 2/20 0.34
KDM4C Q9H3R0 2/20 0.34
KDM2A Q9Y2K7 2/20 0.34
GPR84 Q9NQS5 3/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
ALOX15 P16050 1/20 0.34
NFKB1 P19838 1/20 0.34
PTGS2 P35354 1/20 0.34
THPO P40225 1/20 0.34
RECQL P46063 1/20 0.34
BLM P54132 1/20 0.34
FFAR1 O14842 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7078226 0.76 SMN1; SMN2 (0.52) SMN1; SMN2TET2TET3TET1OR51E2
SCHEMBL7078225 0.76 SMN1; SMN2 (0.52) SMN1; SMN2TET2TET3TET1OR51E2
SCHEMBL7078228 0.76 SMN1; SMN2 (0.52) SMN1; SMN2TET2TET3TET1OR51E2
SCHEMBL22769505 0.76 GRIK1 (0.50)
SCHEMBL8353811 0.76 GRIK1 (0.50)
SCHEMBL14344224 0.76 GRIK1 (0.50)
SCHEMBL9438438 0.74 GRIK1 (0.48)
SCHEMBL18766394 0.73 ALDH1A1 (0.38) SMN1; SMN2KDM4EALDH1A1CRBN
SCHEMBL18057552 0.73 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1TP53
SCHEMBL25660993 0.73 SMN1; SMN2 (0.55) SMN1; SMN2TET2TET3TET1OR51E2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8454986-B2 Silver nanoparticles with specific surface area and a method for producing them JANSSEN PHARMACEUTICA N.V. (BE) 2013-06-04 US disclosed
CN-101977509-A Silver nanoparticles with specific surface area and a method for producing them JANSSEN PHARMACEUTICA NV 2011-02-16 CN disclosed
US-20100272770-A1 SILVER NANOPARTICLES WITH SPECIFIC SURFACE AREA AND A METHOD FOR PRODUCING THEM JANSSEN PHARMACEUTICA N.V. (BE) 2010-10-28 US disclosed
EP-2224815-A1 SILVER NANOPARTICLES WITH SPECIFIC SURFACE AREA AND A METHOD FOR PRODUCING THEM Janssen Pharmaceutica N.V. (BE) 2010-09-08 EP disclosed
WO-2009087122-A1 SILVER NANOPARTICLES WITH SPECIFIC SURFACE AREA AND A METHOD FOR PRODUCING THEM JANSSEN PHARMACEUTICA N.V. (BE) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100272770-A1 SILVER NANOPARTICLES WITH SPECIFIC SURFACE AREA AND A METHOD FOR PRODUCING THEM ARG1, BET1, SOD1 SMN1; SMN2 4198/4885TET2 313/4885TET3 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.